指南与共识抗菌药物管理

感染性疾病药师主导干预对泰国医疗中心抗菌药物管理项目指南依从性的影响

Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center.
指南 / 共识 · Am J Health Syst Pharm · 2022-01-01

在泰国Thammasat大学医院开展准实验研究,比较感染性疾病药师主导干预组与标准抗菌药物管理项目组的指南依从性及临床结局。干预组指南依从性显著高于标准组(79% vs 56.6%;P < 0.001),药师建议接受率为81.8%,碳青霉烯类和磷霉素消耗下降。

要点

  • 感染性疾病药师主导干预可显著提高抗菌药物管理项目指南依从性。
  • 药师建议接受率为81.8%,主要障碍为医生抵触和患者病情严重。
  • 干预组碳青霉烯类和磷霉素消耗显著下降。

核心结论

  • 感染性疾病药师主导干预可改善抗菌药物管理项目指南依从性,并可能减少碳青霉烯类消耗。

研究设计与样本

  • 在泰国Thammasat大学医院开展的准实验研究,时间范围为2019年8月至2020年4月,比较感染性疾病药师主导干预组与标准抗菌药物管理项目组。

主要发现

  • 干预组指南依从性显著高于标准组(79% vs 56.6%;P < 0.001),尤其在适当指征(P < 0.001)、给药方案(P = 0.005)和疗程(P = 0.001)方面。
  • 药师建议接受率为81.8%(44/54),常见障碍为医生抵触(11/20;55%)和患者病情严重(6/20;30%)。
  • 干预组临床治愈率有升高趋势(63.6% vs 56.1%;P = 0.127),30天全因死亡率(15.9% vs 1.5%;P = 0.344)和中位住院时间(20 vs 18天;P = 0.085)两组相似。
  • 干预组碳青霉烯类(P = 0.042)和磷霉素(P = 0.014)消耗下降,多重耐药病原体总体发生率边际显著下降(系数 -5.93;P = 0.049)。

临床怎么用

  • 感染性疾病药师主导的干预可作为提高抗菌药物管理项目指南依从性的策略,尤其关注指征、给药方案和疗程的审核。
  • 针对医生抵触和患者病情严重等障碍,需采取相应沟通与协作措施以提高建议接受率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate and compare antimicrobial stewardship program (ASP) guideline adherence (primary outcome) as well as length of stay, 30-day all-cause mortality, clinical cure, antimicrobial consumption, and incidence of multidrug-resistant (MDR) pathogens (secondary outcomes) between an infectious diseases (ID) pharmacist-led intervention group and a standard ASP group. METHODS: A quasi-experimental study was performed at Thammasat University Hospital between August 2019 and April 2020. Data including baseline characteristics and primary and secondary outcomes were collected from the electronic medical record by the ID pharmacist. RESULTS: The ASP guideline adherence in the ID pharmacist-led intervention group was significantly higher than in the standard ASP group (79% vs 56.6%; P < 0.001), especially with regard to appropriate indication (P < 0.001), dosage regimen (P = 0.005), and duration (P = 0.001). The acceptance rate of ID pharmacist recommendations was 81.8% (44/54). The most common key barriers to following recommendations were physician resistance (11/20; 55%) and high severity of disease in the patient (6/20; 30%). Compared to the standard ASP group, there was a trend toward clinical cure in the ID pharmacist-led intervention group (63.6% vs 56.1%; P = 0.127), while 30-day all-cause mortality (15.9% vs 1.5%; P = 0.344) and median length of stay (20 vs 18 days; P = 0.085) were similar in the 2 groups. Carbapenem (P = 0.042) and fosfomycin (P = 0.014) consumption declined in the ID pharmacist-led intervention group. A marginally significant decrease in the overall incidence of MDR pathogens was also observed in the ID pharmacist-led intervention group (coefficient, -5.93; P = 0.049). CONCLUSION: Our study demonstrates that an ID pharmacist-led intervention can improve ASP guideline adherence and may reduce carbapenem consumption.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Jantarathaneewat K, Montakantikul P, Weber DJ, et al. Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center. Am J Health Syst Pharm. 2022. PMID: 35390112. doi:10.1093/ajhp/zxac107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。